Header Logo

Connection

JOHN KIRKWOOD to Skin Neoplasms

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Skin Neoplasms.
JOHN KIRKWOOD
Connection Strength
31.743
Skin Neoplasms
  1. Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76?K trial. Eur J Cancer. 2025 May 02; 220:115371.
    View in: PubMed
    Score: 0.571
  2. Differences in the pathological, transcriptomic, and prognostic implications of lymphoid structures between primary and metastatic cutaneous melanomas. J Immunother Cancer. 2024 Nov 12; 12(11).
    View in: PubMed
    Score: 0.558
  3. Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C?melanoma is removed by surgery. Future Oncol. 2024 May; 20(15):959-968.
    View in: PubMed
    Score: 0.531
  4. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med. 2023 Nov; 29(11):2835-2843.
    View in: PubMed
    Score: 0.518
  5. Early Detection and Prognostic Assessment of Cutaneous Melanoma: Consensus on Optimal Practice and the Role of Gene Expression Profile Testing. JAMA Dermatol. 2023 05 01; 159(5):545-553.
    View in: PubMed
    Score: 0.501
  6. Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023 01 10; 41(2):186-197.
    View in: PubMed
    Score: 0.481
  7. Multiple primary melanoma in association with other personal and familial cancers. Cancer Med. 2023 02; 12(3):2474-2483.
    View in: PubMed
    Score: 0.476
  8. Poorer survival outcomes in patients with multiple versus single primary melanoma. Cancer. 2022 06 01; 128(11):2098-2106.
    View in: PubMed
    Score: 0.464
  9. Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. J Immunother Cancer. 2022 01; 10(1).
    View in: PubMed
    Score: 0.457
  10. Neratinib kills B-RAF V600E melanoma via ROS-dependent autophagosome formation and death receptor signaling. Pigment Cell Melanoma Res. 2022 01; 35(1):66-77.
    View in: PubMed
    Score: 0.447
  11. Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis. J Immunother Cancer. 2021 05; 9(5).
    View in: PubMed
    Score: 0.437
  12. Indoor tanning exposure in association with multiple primary melanoma. Cancer. 2021 02 15; 127(4):560-568.
    View in: PubMed
    Score: 0.423
  13. State of Melanoma: An Historic Overview of a Field in Transition. Hematol Oncol Clin North Am. 2021 02; 35(1):1-27.
    View in: PubMed
    Score: 0.421
  14. Developing agents for the therapeutic prevention of melanoma: can the assessment of cutaneous precursor lesions help? Future Oncol. 2020 Mar; 16(9):413-415.
    View in: PubMed
    Score: 0.402
  15. Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol. 2020 02 20; 38(6):567-575.
    View in: PubMed
    Score: 0.398
  16. Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
    View in: PubMed
    Score: 0.379
  17. Neoadjuvant ipilimumab (3?mg/kg or 10?mg/kg) and high dose IFN-a2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018 10 23; 6(1):112.
    View in: PubMed
    Score: 0.367
  18. Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila). 2018 07; 11(7):429-438.
    View in: PubMed
    Score: 0.354
  19. Adjuvant Therapy in Resected Melanoma. N Engl J Med. 2018 02 15; 378(7):679-680.
    View in: PubMed
    Score: 0.350
  20. A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma. Melanoma Res. 2017 10; 27(5):429-438.
    View in: PubMed
    Score: 0.341
  21. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. N Engl J Med. 2017 11 09; 377(19):1813-1823.
    View in: PubMed
    Score: 0.339
  22. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.337
  23. A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol. 2017 Aug 01; 3(8):1112-1115.
    View in: PubMed
    Score: 0.337
  24. Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma. Melanoma Res. 2017 08; 27(4):342-350.
    View in: PubMed
    Score: 0.337
  25. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer. 2017 Jul 15; 123(14):2688-2697.
    View in: PubMed
    Score: 0.328
  26. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-a-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol. 2017 Mar 10; 35(8):885-892.
    View in: PubMed
    Score: 0.325
  27. Downstream consequences of melanoma screening in a community practice setting: First results. Cancer. 2016 Oct 15; 122(20):3152-3156.
    View in: PubMed
    Score: 0.313
  28. BRAF Inhibitors and IFNa: Plus, Minus, or Indeterminate? J Natl Cancer Inst. 2016 Jul; 108(7).
    View in: PubMed
    Score: 0.304
  29. Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. J Transl Med. 2015 Sep 30; 13:319.
    View in: PubMed
    Score: 0.296
  30. Unfolding the mutational landscape of human melanoma. J Invest Dermatol. 2015 Mar; 135(3):659-662.
    View in: PubMed
    Score: 0.285
  31. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014 Nov 05; 312(17):1744-53.
    View in: PubMed
    Score: 0.278
  32. State of melanoma: an historic overview of a field in transition. Hematol Oncol Clin North Am. 2014 Jun; 28(3):415-35.
    View in: PubMed
    Score: 0.270
  33. Serologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfa. Melanoma Res. 2014 Apr; 24(2):150-7.
    View in: PubMed
    Score: 0.267
  34. ECOG phase II trial of graded-dose peginterferon a-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Clin Cancer Res. 2013 Dec 01; 19(23):6597-604.
    View in: PubMed
    Score: 0.259
  35. Pediatric melanoma: analysis of an international registry. Cancer. 2013 Nov 15; 119(22):4012-9.
    View in: PubMed
    Score: 0.257
  36. Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approach. Clin Dermatol. 2013 May-Jun; 31(3):237-50.
    View in: PubMed
    Score: 0.251
  37. Safety and efficacy of decitabine in combination with temozolomide in metastatic melanoma: a phase I/II study and pharmacokinetic analysis. Ann Oncol. 2013 Apr; 24(4):1112-9.
    View in: PubMed
    Score: 0.243
  38. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy? J Clin Oncol. 2012 Nov 01; 30(31):3773-6.
    View in: PubMed
    Score: 0.241
  39. Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012 Oct; 29(7):775-96.
    View in: PubMed
    Score: 0.239
  40. New therapies in the treatment of melanoma. Expert Opin Investig Drugs. 2012 Nov; 21(11):1643-59.
    View in: PubMed
    Score: 0.238
  41. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol. 2012 Jan 20; 30(3):322-8.
    View in: PubMed
    Score: 0.228
  42. Neoadjuvant therapy for high-risk bulky regional melanoma. J Surg Oncol. 2011 Sep; 104(4):386-90.
    View in: PubMed
    Score: 0.223
  43. Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin. Clin Cancer Res. 2011 Oct 15; 17(20):6574-81.
    View in: PubMed
    Score: 0.223
  44. A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma. Cancer. 2011 Oct 15; 117(20):4732-9.
    View in: PubMed
    Score: 0.217
  45. Immunogenicity for CD8+ and CD4+ T cells of 2 formulations of an incomplete freund's adjuvant for multipeptide melanoma vaccines. J Immunother. 2010 Jul-Aug; 33(6):630-8.
    View in: PubMed
    Score: 0.206
  46. Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (t4) primary melanoma: pathologic analysis of the e1690 and e1694 intergroup trials. Am J Clin Pathol. 2010 Apr; 133(4):646-53.
    View in: PubMed
    Score: 0.202
  47. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin Cancer Res. 2010 Feb 01; 16(3):1042-8.
    View in: PubMed
    Score: 0.200
  48. Melanoma in pediatric, adolescent, and young adult patients. Semin Oncol. 2009 Oct; 36(5):419-31.
    View in: PubMed
    Score: 0.196
  49. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy. J Clin Oncol. 2009 Jun 01; 27(16):2583-5.
    View in: PubMed
    Score: 0.189
  50. Predictors of response to interferon therapy. Curr Opin Oncol. 2009 Mar; 21(2):138-43.
    View in: PubMed
    Score: 0.188
  51. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 2009 Feb 15; 115(4):859-68.
    View in: PubMed
    Score: 0.187
  52. Next generation of immunotherapy for melanoma. J Clin Oncol. 2008 Jul 10; 26(20):3445-55.
    View in: PubMed
    Score: 0.180
  53. STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. J Invest Dermatol. 2008 Aug; 128(8):1997-2002.
    View in: PubMed
    Score: 0.175
  54. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 01; 26(4):527-34.
    View in: PubMed
    Score: 0.174
  55. Management of metastatic melanoma. Semin Oncol. 2007 Dec; 34(6):532-45.
    View in: PubMed
    Score: 0.172
  56. Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents. Melanoma Res. 2007 Jun; 17(3):193-200.
    View in: PubMed
    Score: 0.166
  57. Oblimersen in the treatment of metastatic melanoma. Future Oncol. 2007 Jun; 3(3):263-71.
    View in: PubMed
    Score: 0.166
  58. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res. 2007 Mar 01; 13(5):1523-31.
    View in: PubMed
    Score: 0.164
  59. Molecularly targeted therapy for melanoma: current reality and future options. Cancer. 2006 Nov 15; 107(10):2317-27.
    View in: PubMed
    Score: 0.160
  60. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol. 2006 Jul 01; 24(19):3164-71.
    View in: PubMed
    Score: 0.156
  61. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2331s-2336s.
    View in: PubMed
    Score: 0.153
  62. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med. 2006 Feb 16; 354(7):709-18.
    View in: PubMed
    Score: 0.152
  63. Does childhood vaccination and exposure to infection improve long-term survival in patients with malignant melanoma? Nat Clin Pract Oncol. 2005 May; 2(5):240-1.
    View in: PubMed
    Score: 0.144
  64. Transcriptomic signatures in peripheral CD4+T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation. Front Immunol. 2025; 16:1529707.
    View in: PubMed
    Score: 0.143
  65. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Long-term follow-up, crossover, and rechallenge with pembrolizumab in the phase III KEYNOTE-716 study. Eur J Cancer. 2025 May 02; 220:115381.
    View in: PubMed
    Score: 0.143
  66. Melanoma. Cancer Chemother Biol Response Modif. 2005; 22:563-90.
    View in: PubMed
    Score: 0.141
  67. Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group. J Clin Oncol. 2025 Mar 20; 43(9):1157-1167.
    View in: PubMed
    Score: 0.138
  68. Treatment outcomes following partial shave biopsy of atypical and malignant melanocytic tumors in pediatric patients. Melanoma Res. 2024 12 01; 34(6):544-548.
    View in: PubMed
    Score: 0.138
  69. Melanoma in the older person. Oncology (Williston Park). 2004 Aug; 18(9):1187-96; discussion 1196-7.
    View in: PubMed
    Score: 0.137
  70. Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2024 11 07; 391(18):1709-1720.
    View in: PubMed
    Score: 0.136
  71. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004 Apr 15; 100(8):1692-8.
    View in: PubMed
    Score: 0.134
  72. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. J Immunother Cancer. 2024 Mar 13; 12(3).
    View in: PubMed
    Score: 0.133
  73. Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. J Clin Oncol. 2024 May 10; 42(14):1619-1624.
    View in: PubMed
    Score: 0.133
  74. Prognostic gene expression profile testing to inform use of adjuvant therapy: A survey of melanoma experts. Cancer Med. 2023 12; 12(24):22103-22108.
    View in: PubMed
    Score: 0.131
  75. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma. J Immunother Cancer. 2023 10; 11(10).
    View in: PubMed
    Score: 0.129
  76. Systemic Therapy for Melanoma: ASCO Guideline Update. J Clin Oncol. 2023 10 20; 41(30):4794-4820.
    View in: PubMed
    Score: 0.128
  77. Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study. J Immunother Cancer. 2023 06; 11(6).
    View in: PubMed
    Score: 0.126
  78. Medical management of melanoma. Surg Clin North Am. 2003 Apr; 83(2):283-322, viii.
    View in: PubMed
    Score: 0.125
  79. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med. 2023 03 02; 388(9):813-823.
    View in: PubMed
    Score: 0.124
  80. Adjuvant therapy of melanoma. Semin Cutan Med Surg. 2003 Mar; 22(1):55-67.
    View in: PubMed
    Score: 0.124
  81. Melanoma vaccines: early progress and future promises. Semin Cutan Med Surg. 2003 Mar; 22(1):68-75.
    View in: PubMed
    Score: 0.124
  82. Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases. Clin Cancer Res. 2023 02 01; 29(3):521-531.
    View in: PubMed
    Score: 0.123
  83. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study. Cancer. 2003 Jan 01; 97(1):121-7.
    View in: PubMed
    Score: 0.123
  84. Sentinel lymph node biopsy and adjuvant therapy for melanoma: evidence revisited. Arch Dermatol. 2003 Jan; 139(1):99; author reply 99-100.
    View in: PubMed
    Score: 0.123
  85. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Forum (Genova). 2003; 13(2):127-40; quiz 187-8.
    View in: PubMed
    Score: 0.123
  86. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022 12; 10(12).
    View in: PubMed
    Score: 0.122
  87. TPP1 promoter mutations cooperate with TERT promoter mutations to lengthen telomeres in melanoma. Science. 2022 Nov 11; 378(6620):664-668.
    View in: PubMed
    Score: 0.121
  88. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2022 11; 23(11):1378-1388.
    View in: PubMed
    Score: 0.121
  89. Use and abuse of statistics in evidence-based medicine. J Clin Oncol. 2002 Oct 01; 20(19):4122-3; author reply 4123-4.
    View in: PubMed
    Score: 0.120
  90. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002 Sep 01; 95(5):1101-12.
    View in: PubMed
    Score: 0.120
  91. Update on adjuvant interferon therapy for high-risk melanoma. Oncology (Williston Park). 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197.
    View in: PubMed
    Score: 0.120
  92. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol. 2022 11 10; 40(32):3741-3749.
    View in: PubMed
    Score: 0.118
  93. Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. J Transl Med. 2022 06 03; 20(1):253.
    View in: PubMed
    Score: 0.118
  94. Clinically Significant Risk Thresholds in the Management of Primary Cutaneous Melanoma: A Survey of Melanoma Experts. Ann Surg Oncol. 2022 Sep; 29(9):5948-5956.
    View in: PubMed
    Score: 0.117
  95. A retrospective analysis of the impact of the COVID-19 pandemic on staging at presentation of patients with invasive melanoma. J Am Acad Dermatol. 2022 10; 87(4):906-908.
    View in: PubMed
    Score: 0.117
  96. Five-Year Outcomes of a Melanoma Screening Initiative in a Large Health Care System. JAMA Dermatol. 2022 05 01; 158(5):504-512.
    View in: PubMed
    Score: 0.117
  97. An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
    View in: PubMed
    Score: 0.114
  98. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001 Sep; 137(9):1217-24.
    View in: PubMed
    Score: 0.112
  99. Targeted therapy for malignant melanoma. Curr Oncol Rep. 2001 Jul; 3(4):344-52.
    View in: PubMed
    Score: 0.110
  100. Neoadjuvant Pembrolizumab and High-Dose IFNa-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res. 2021 08 01; 27(15):4195-4204.
    View in: PubMed
    Score: 0.108
  101. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol. 2001 Mar 01; 19(5):1430-6.
    View in: PubMed
    Score: 0.108
  102. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 02 05; 371(6529):595-602.
    View in: PubMed
    Score: 0.107
  103. CTLA-4 blockade and interferon-a induce proinflammatory transcriptional changes in the tumor immune landscape that correlate with pathologic response in melanoma. PLoS One. 2021; 16(1):e0245287.
    View in: PubMed
    Score: 0.107
  104. The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res. 2021 05 15; 27(10):2678-2697.
    View in: PubMed
    Score: 0.107
  105. Dysregulated NF-?B-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunol Res. 2020 12; 8(12):1554-1567.
    View in: PubMed
    Score: 0.105
  106. Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker. Cancer Med. 2020 11; 9(22):8650-8661.
    View in: PubMed
    Score: 0.105
  107. Biologic therapy. Clin Plast Surg. 2000 Oct; 27(4):643-65.
    View in: PubMed
    Score: 0.105
  108. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med. 2020 09 17; 383(12):1139-1148.
    View in: PubMed
    Score: 0.104
  109. Prognostic Gene Expression Profiling in Cutaneous Melanoma: Identifying the Knowledge Gaps and Assessing the Clinical Benefit. JAMA Dermatol. 2020 09 01; 156(9):1004-1011.
    View in: PubMed
    Score: 0.104
  110. Update on the role of adjuvant interferon for high risk melanoma. Forum (Genova). 2000 Jul-Sep; 10(3):230-9.
    View in: PubMed
    Score: 0.103
  111. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer. 2000 Jun 15; 88(12):2693-702.
    View in: PubMed
    Score: 0.103
  112. Clinical Development of BRAF plus MEK Inhibitor Combinations. Trends Cancer. 2020 09; 6(9):797-810.
    View in: PubMed
    Score: 0.103
  113. Adjuvant interferon in the treatment of melanoma. Br J Cancer. 2000 May; 82(10):1755-6.
    View in: PubMed
    Score: 0.102
  114. Prognosis and Management of BRAF V600E-Mutated Pregnancy-Associated Melanoma. Oncologist. 2020 08; 25(8):e1209-e1220.
    View in: PubMed
    Score: 0.101
  115. Granulocyte-macrophage colony-stimulating factor: another cytokine with adjuvant therapeutic benefit in melanoma? J Clin Oncol. 2000 Apr; 18(8):1603-5.
    View in: PubMed
    Score: 0.101
  116. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 11 20; 38(33):3947-3970.
    View in: PubMed
    Score: 0.101
  117. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
    View in: PubMed
    Score: 0.100
  118. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000; 5(2):144-51.
    View in: PubMed
    Score: 0.100
  119. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
    View in: PubMed
    Score: 0.099
  120. Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. J Immunother Cancer. 2019 09 04; 7(1):239.
    View in: PubMed
    Score: 0.097
  121. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999 Sep; 17(9):2745-51.
    View in: PubMed
    Score: 0.097
  122. Thick melanoma is associated with low melanoma knowledge and low perceived health competence, but not delays in care. J Am Acad Dermatol. 2020 08; 83(2):587-590.
    View in: PubMed
    Score: 0.096
  123. Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 05; 20(5):701-710.
    View in: PubMed
    Score: 0.094
  124. Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions. Mol Med. 1999 Jan; 5(1):11-20.
    View in: PubMed
    Score: 0.093
  125. Psychosocial impact of skin biopsies in the setting of melanoma screening: a cross-sectional survey. Br J Dermatol. 2019 03; 180(3):664-665.
    View in: PubMed
    Score: 0.092
  126. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600-Mutant Stage III Melanoma. J Clin Oncol. 2018 12 10; 36(35):3441-3449.
    View in: PubMed
    Score: 0.092
  127. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019 01 01; 125(1):18-44.
    View in: PubMed
    Score: 0.091
  128. Adjuvant interferon treatment for melanoma. Hematol Oncol Clin North Am. 1998 Aug; 12(4):823-33.
    View in: PubMed
    Score: 0.090
  129. Adjuvant IFN alpha2 therapy of melanoma. Lancet. 1998 Jun 27; 351(9120):1901-3.
    View in: PubMed
    Score: 0.090
  130. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 07; 19(7):916-929.
    View in: PubMed
    Score: 0.089
  131. Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma. Melanoma Res. 2018 06; 28(3):211-221.
    View in: PubMed
    Score: 0.089
  132. Adjuvant therapy of melanoma. Semin Surg Oncol. 1998 Jun; 14(4):302-10.
    View in: PubMed
    Score: 0.089
  133. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. J Immunother Cancer. 2018 05 30; 6(1):44.
    View in: PubMed
    Score: 0.089
  134. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.087
  135. Management strategies of academic pigmented lesion clinic directors in the United States. J Am Acad Dermatol. 2018 Aug; 79(2):367-369.
    View in: PubMed
    Score: 0.087
  136. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. J Natl Cancer Inst. 2018 01 01; 110(1).
    View in: PubMed
    Score: 0.087
  137. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Ann Surg Oncol. 2018 Feb; 25(2):356-377.
    View in: PubMed
    Score: 0.086
  138. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 02 01; 36(4):399-413.
    View in: PubMed
    Score: 0.086
  139. Estimating the cost of skin cancer detection by dermatology providers in a large health care system. J Am Acad Dermatol. 2018 04; 78(4):701-709.e1.
    View in: PubMed
    Score: 0.086
  140. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. J Clin Oncol. 2018 02 01; 36(4):391-398.
    View in: PubMed
    Score: 0.085
  141. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492.
    View in: PubMed
    Score: 0.085
  142. High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585.
    View in: PubMed
    Score: 0.085
  143. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer. 2017 09 19; 5(1):74.
    View in: PubMed
    Score: 0.085
  144. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
    View in: PubMed
    Score: 0.085
  145. Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017 08 15; 5(1):67.
    View in: PubMed
    Score: 0.084
  146. Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017 09; 82:171-183.
    View in: PubMed
    Score: 0.084
  147. Interferon adjuvant therapy of melanoma. Cancer. 1997 May 01; 79(9):1843-6.
    View in: PubMed
    Score: 0.083
  148. The adjuvant treatment of malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):147-52.
    View in: PubMed
    Score: 0.082
  149. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol. 1997 Feb; 24(1 Suppl 4):S16-23.
    View in: PubMed
    Score: 0.081
  150. Adjuvant application of interferons. Semin Oncol. 1996 Dec; 23(6):737-43.
    View in: PubMed
    Score: 0.080
  151. Malignant melanoma metastatic to the tonsil. Laryngoscope. 1996 Mar; 106(3 Pt 1):313-6.
    View in: PubMed
    Score: 0.076
  152. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan; 14(1):7-17.
    View in: PubMed
    Score: 0.075
  153. Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi. J Invest Dermatol. 2016 Jan; 136(1):339-342.
    View in: PubMed
    Score: 0.075
  154. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995 Nov-Dec; 1(4):274-80.
    View in: PubMed
    Score: 0.075
  155. Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015 Dec 01; 33(34):4066-76.
    View in: PubMed
    Score: 0.074
  156. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015 Aug; 16(8):908-18.
    View in: PubMed
    Score: 0.073
  157. IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells. Cancer Res. 2015 Apr 15; 75(8):1635-44.
    View in: PubMed
    Score: 0.071
  158. Addressing the knowledge gap in clinical recommendations for management and complete excision of clinically atypical nevi/dysplastic nevi: Pigmented Lesion Subcommittee consensus statement. JAMA Dermatol. 2015 Feb; 151(2):212-8.
    View in: PubMed
    Score: 0.071
  159. Atypical Spitzoid neoplasms: a review of potential markers of biological behavior including sentinel node biopsy. Melanoma Res. 2014 Oct; 24(5):437-47.
    View in: PubMed
    Score: 0.069
  160. Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res. 2014 Jun; 24(3):207-18.
    View in: PubMed
    Score: 0.068
  161. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
    View in: PubMed
    Score: 0.066
  162. A four-marker signature of TNF-RII, TGF-a, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma. J Transl Med. 2014 Jan 23; 12:19.
    View in: PubMed
    Score: 0.066
  163. Advances in adjuvant therapy: potential for prognostic and predictive biomarkers. Methods Mol Biol. 2014; 1102:45-69.
    View in: PubMed
    Score: 0.066
  164. Pathologic and gene expression features of metastatic melanomas to the brain. Cancer. 2013 Aug 01; 119(15):2737-46.
    View in: PubMed
    Score: 0.063
  165. Dysplastic nevi in relation to superficial spreading melanoma. Cancer Epidemiol Biomarkers Prev. 1993 Mar-Apr; 2(2):99-101.
    View in: PubMed
    Score: 0.062
  166. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013 Feb 10; 31(5):616-22.
    View in: PubMed
    Score: 0.061
  167. An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol. 1992 Nov; 27(5 Pt 1):741-9.
    View in: PubMed
    Score: 0.061
  168. Characterization of an early passage Merkel cell polyomavirus-positive Merkel cell carcinoma cell line, MS-1, and its growth in NOD scid gamma mice. J Virol Methods. 2013 Jan; 187(1):6-14.
    View in: PubMed
    Score: 0.060
  169. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012 Jul 09; 10:85.
    View in: PubMed
    Score: 0.059
  170. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
    View in: PubMed
    Score: 0.059
  171. Interclinician agreement on the recognition of selected gross morphologic features of pigmented lesions. Studies of melanocytic nevi V. J Am Acad Dermatol. 1992 Feb; 26(2 Pt 1):185-90.
    View in: PubMed
    Score: 0.057
  172. Comparison of nonfamilial and familial melanoma. Dermatology. 1992; 184(1):2-7.
    View in: PubMed
    Score: 0.057
  173. Studies of interferons in the therapy of melanoma. Semin Oncol. 1991 Oct; 18(5 Suppl 7):83-90.
    View in: PubMed
    Score: 0.056
  174. Inter-clinician agreement on the recognition of clinical pigmentary characteristics of patients with cutaneous malignant melanoma. Studies of melanocytic nevi, VI. Br J Cancer. 1991 Aug; 64(2):373-6.
    View in: PubMed
    Score: 0.056
  175. A relation between childhood sun exposure and dysplastic nevus syndrome among patients with nonfamilial melanoma. Epidemiology. 1991 May; 2(3):210-4.
    View in: PubMed
    Score: 0.055
  176. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16(1):5-24.
    View in: PubMed
    Score: 0.053
  177. Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer. 2010 Sep 15; 116(18):4326-33.
    View in: PubMed
    Score: 0.052
  178. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med. 2010 Aug 16; 8:76.
    View in: PubMed
    Score: 0.052
  179. Meeting report from the Third Global Workshop on Melanoma. Pigment Cell Melanoma Res. 2010 Oct; 23(5):e1-7.
    View in: PubMed
    Score: 0.052
  180. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
    View in: PubMed
    Score: 0.051
  181. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer. 2010 Mar 15; 116(6):1526-34.
    View in: PubMed
    Score: 0.050
  182. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.
    View in: PubMed
    Score: 0.049
  183. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs. 2011 Feb; 29(1):161-6.
    View in: PubMed
    Score: 0.049
  184. Human Merkel cell polyomavirus infection I. MCV T antigen expression in Merkel cell carcinoma, lymphoid tissues and lymphoid tumors. Int J Cancer. 2009 Sep 15; 125(6):1243-9.
    View in: PubMed
    Score: 0.049
  185. Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma. J Transl Med. 2009 Jul 29; 7:68.
    View in: PubMed
    Score: 0.048
  186. A phase 2 trial of sequential temozolomide chemotherapy followed by high-dose interleukin 2 immunotherapy for metastatic melanoma. Cancer. 2008 Oct 01; 113(7):1632-40.
    View in: PubMed
    Score: 0.046
  187. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother. 2008 Oct; 31(8):781-91.
    View in: PubMed
    Score: 0.046
  188. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med. 1988 May; 17(3):273-9.
    View in: PubMed
    Score: 0.044
  189. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer. 2008 Mar 01; 112(5):982-94.
    View in: PubMed
    Score: 0.044
  190. Safety and efficacy of arsenic trioxide for patients with advanced metastatic melanoma. Cancer. 2008 Mar 01; 112(5):1131-8.
    View in: PubMed
    Score: 0.044
  191. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol. 2008 Feb 20; 26(6):955-62.
    View in: PubMed
    Score: 0.044
  192. Dysplastic nevi in association with multiple primary melanoma. Cancer Res. 1988 Feb 15; 48(4):1016-8.
    View in: PubMed
    Score: 0.044
  193. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol. 2007 Sep 01; 25(25):3802-7.
    View in: PubMed
    Score: 0.042
  194. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res. 2007 Apr 15; 13(8):2422-8.
    View in: PubMed
    Score: 0.041
  195. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg. 2007; 54:241-7.
    View in: PubMed
    Score: 0.040
  196. Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features. Ann Surg Oncol. 2006 Dec; 13(12):1664-70.
    View in: PubMed
    Score: 0.040
  197. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006 Oct 10; 24(29):4738-45.
    View in: PubMed
    Score: 0.040
  198. Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. Melanoma Res. 2006 Apr; 16(2):165-74.
    View in: PubMed
    Score: 0.038
  199. Innovations and challenges in melanoma: summary statement from the first Cambridge conference. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2291s-2296s.
    View in: PubMed
    Score: 0.038
  200. Radiosurgery for the treatment of spinal melanoma metastases. Stereotact Funct Neurosurg. 2005; 83(5-6):213-21.
    View in: PubMed
    Score: 0.038
  201. Antigenic phenotype of pigment cell lesions: a study of melanoma, its precursor lesions and heterogeneity in metastatic melanoma. J Invest Dermatol. 1985 May; 84(5):430-2.
    View in: PubMed
    Score: 0.036
  202. Vitiligo and melanoma: can genetically abnormal melanocytes result in both vitiligo and melanoma within a single family? J Am Acad Dermatol. 1984 Oct; 11(4 Pt 1):696-701.
    View in: PubMed
    Score: 0.035
  203. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004 Jun 01; 22(11):2101-7.
    View in: PubMed
    Score: 0.034
  204. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4.
    View in: PubMed
    Score: 0.034
  205. Randomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanoma. J Clin Oncol. 1984 Mar; 2(3):164-8.
    View in: PubMed
    Score: 0.033
  206. Regional isolated perfusion of high risk melanoma of the extremities with imidazole carboxamide. Surg Gynecol Obstet. 1984 Mar; 158(3):238-42.
    View in: PubMed
    Score: 0.033
  207. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004 Jan 01; 22(1):11-4.
    View in: PubMed
    Score: 0.033
  208. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003; 21(1):43-52.
    View in: PubMed
    Score: 0.031
  209. Fluorescence imaging analysis of upstream regulators and downstream targets of STAT3 in melanoma precursor lesions obtained from patients before and after systemic low-dose interferon-alpha treatment. Mol Imaging. 2003 Jan; 2(1):65-73.
    View in: PubMed
    Score: 0.031
  210. Granulomatous lymphangitis. A complication of intralymphatic immunotherapy with methanol extraction residue of BCG (MER). Cancer. 1982 Oct 01; 50(7):1299-303.
    View in: PubMed
    Score: 0.030
  211. Implications of microscopic satellites of the primary and extracapsular lymph node spread in patients with high-risk melanoma: pathologic corollary of Eastern Cooperative Oncology Group Trial E1690. J Clin Oncol. 2002 Apr 15; 20(8):2053-7.
    View in: PubMed
    Score: 0.029
  212. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002 Mar 01; 20(5):1311-8.
    View in: PubMed
    Score: 0.029
  213. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
    View in: PubMed
    Score: 0.029
  214. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec; 8(10):766-70.
    View in: PubMed
    Score: 0.028
  215. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001 Aug 15; 19(16):3622-34.
    View in: PubMed
    Score: 0.028
  216. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001 Aug 15; 19(16):3635-48.
    View in: PubMed
    Score: 0.028
  217. Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res. 2000 Aug; 9(3):352-63.
    View in: PubMed
    Score: 0.026
  218. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020 07 17; 5(49).
    View in: PubMed
    Score: 0.026
  219. Cytokine-based therapy for melanoma: pre-clinical studies. Forum (Genova). 2000 Jul-Sep; 10(3):204-26.
    View in: PubMed
    Score: 0.026
  220. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000 Mar 15; 88(6):1484-91.
    View in: PubMed
    Score: 0.025
  221. Melanoma: a multidisciplinary overview of current concepts and management. Conn Med. 1980 Jan; 44(1):21-6.
    View in: PubMed
    Score: 0.025
  222. Recent advances in the care of the patient with malignant melanoma. Ann Surg. 1997 Jan; 225(1):1-14.
    View in: PubMed
    Score: 0.020
  223. Molecular analysis of melanoma precursor lesions. Cell Growth Differ. 1996 Dec; 7(12):1733-40.
    View in: PubMed
    Score: 0.020
  224. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996 Oct; 14(10):2666-73.
    View in: PubMed
    Score: 0.020
  225. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
    View in: PubMed
    Score: 0.017
  226. Interferons in the therapy of solid tumors. Oncology. 1994 Mar-Apr; 51(2):129-36.
    View in: PubMed
    Score: 0.017
  227. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013 10; 10(10):588-98.
    View in: PubMed
    Score: 0.016
  228. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res. 1991 Dec 15; 51(24):6691-4.
    View in: PubMed
    Score: 0.014
  229. Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med. 2011 May 26; 9:78.
    View in: PubMed
    Score: 0.014
  230. Human melanocytes cultured from nevi and melanomas. J Invest Dermatol. 1986 Jul; 87(1):95-101.
    View in: PubMed
    Score: 0.010
  231. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res. 1985 Apr; 45(4):1855-61.
    View in: PubMed
    Score: 0.009
  232. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983 Nov; 9(5):689-96.
    View in: PubMed
    Score: 0.008
  233. Uveal findings in patients with cutaneous melanoma. Am J Ophthalmol. 1983 Apr; 95(4):474-9.
    View in: PubMed
    Score: 0.008
  234. Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma. Mol Med. 1999 Dec; 5(12):785-94.
    View in: PubMed
    Score: 0.006
  235. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial. Cancer Treat Rep. 1984 May; 68(5):723-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.